Phase I/II safety and efficacy study of image guided intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab in metastatic melanoma patients

被引：0
|
作者：
Johnson, Daniel Johnson H. [1 ]
Lecagoonporn, Srisuda [1 ]
Bernatchez, Chantale [1 ]
Haymaker, Cara [1 ]
Bentebibel, Salah [1 ]
Uemura, Marc [1 ]
Yee, Cassian [1 ]
Amaria, Rodabe [1 ]
Patel, Sapna [1 ]
Tawbi, Hussein [1 ]
Glitza, Isabella [1 ]
Davies, Michael A. [1 ]
Wong, Michael K. [1 ]
Hwu, Wen-Jen [1 ]
Hwu, Patrick [1 ]
Overwijk, Willem [1 ]
Diab, Adi [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P230
引用
收藏
页数：1
相关论文
共 43 条
  • [11] PBTC-051: FIRST IN PEDIATRICS PHASE 1 STUDY OF CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M IN PEDIATRIC SUBJECTS WITH RECURRENT/REFRACTORY BRAIN TUMORS
    Lindsay, Holly
    Onar-Thomas, Arzu
    Kocak, Mehmet
    Poussaint, Tina Young
    Dhall, Girish
    Broniscer, Alberto
    Vinitsky, Anna
    MacDonald, Tobey
    Trifan, Ovid
    Fangusaro, Jason
    Dunkel, Ira
    NEURO-ONCOLOGY, 2020, 22 : 304 - 304
  • [12] A phase II trial with safety lead-in to evaluate the addition of APX005M, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin chemotherapy for the treatment of advanced soft tissue sarcoma
    Ingham, Matthew
    Lee, Shing Mirn
    Doshi, Sahil
    Hernandez, Susana
    Singh-Kandah, Shahnaz V.
    Singer, Zoe
    Trifan, Ovidiu C.
    Schwartz, Gary K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [13] A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients
    O'Hara, Mark H.
    O'Reilly, Eileen M.
    Rosemarie, Mick
    Varadhachary, Gauri
    Wainberg, Zev A.
    Ko, Andrew
    Fisher, George A.
    Rahma, Osama
    Lyman, Jaclyn P.
    Cabanski, Christopher R.
    Carpenter, Erica L.
    Hollmann, Travis
    Gherardini, Pier Federico
    Kitch, Lacey
    Selinsky, Cheryl
    LaVallee, Theresa
    Trifan, Ovid C.
    Dugan, Ute
    Hubbard-Lucey, Vanessa M.
    Vonderheide, Robert H.
    CANCER RESEARCH, 2019, 79 (13)
  • [14] Clinical and biomarker analyses of intratumoral CD40 agonist sotigalimab in combination with pembrolizumab in metastatic melanoma: A phase I/II trial
    Bentebibel, S-E.
    McGrail, D.
    Wahab, R. Abdel
    Kochat, V.
    Arslan, E.
    Pazdrak, B.
    Tahon, N. H.
    Amaria, R. N.
    Glitza, I. C.
    Patel, S.
    Wong, M. K. K.
    Tawbi, H. A.
    Mcquade, J.
    Davies, M.
    Bernatchez, C.
    Burks, J.
    Rai, K.
    Ekmekcioglu, S.
    Lizee, L.
    Diab, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S242 - S242
  • [15] Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results.
    O'Hara, Mark H.
    O'Reilly, Eileen Mary
    Wolff, Robert A.
    Wainberg, Zev A.
    Ko, Andrew H.
    Rahma, Osama E.
    Fisher, George A.
    Lyman, Jaclyn Paige
    Cabanski, Christopher R.
    Karakunnel, Joyson Joseph
    Gherardini, Pier Federico
    Kitch, Lacey J.
    Bucktrout, Samantha
    Christopher, Elizabeth
    Mick, Rosemarie
    Chen, Richard
    Trifan, Ovidiu C.
    Salvador, Lisa
    O'Donnell-Tormey, Jill
    Vonderheide, Robert H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [16] Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma
    Bajor, David L.
    Mick, Rosemarie
    Riese, Matthew J.
    Richman, Lee P.
    Xu, Xiaowei
    Torigian, Drew A.
    Stelekati, Erietta
    Sweeney, Martha
    Sullivan, Brendan
    Schuchter, Lynn M.
    Amaravadi, Ravi
    Wherry, E. John
    Vonderheide, Robert H.
    CANCER RESEARCH, 2015, 75
  • [17] Phase I study of combination immunotherapy with agonistic CD40 monoclonal antibody (mAb) CP-870,893 (aCD40) and anti-CTLA-4 antibody tremelimumab (treme) in patients with metastatic melanoma
    Bajor, David L.
    Mick, Rosemarie
    Riese, Matthew J.
    Lee, Richman P.
    Xu, Xiaowei
    Torigian, Drew A.
    Stelekati, Erietta
    Sweeney, Martha
    Sullivan, Brendan J.
    Schuchter, Lynn M.
    Amaravadi, Ravi
    Wherry, E. John
    Vonderheide, Robert H.
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10)
  • [18] PHASE 1 STUDY OF THE CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M (SOTIGALIMAB) IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH RECURRENT OR PROGRESSIVE CNS TUMORS AND NEWLY DIAGNOSED BRAIN STEM GLIOMA: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY (PBTC-051; NCT03389802)
    Lindsay, Holly B.
    Billups, Catherine
    Baxter, Patricia
    Hwang, Eugene
    Lenzen, Alicia
    MacDonald, Tobey
    Pollack, Ian F.
    Robison, Nathan
    Vinitsky, Anna
    Poussaint, Tina Young
    Onar-Thomas, Arzu
    Fangusaro, Jason
    Dunkel, Ira J.
    NEURO-ONCOLOGY, 2024, 26
  • [19] Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients
    Jacobs, Joannes F. M.
    Punt, Cornelis J. A.
    Lesterhuis, W. Joost
    Sutmuller, Roger P. M.
    Brouwer, H. Mary-lene H.
    Scharenborg, Nicole M.
    Klasen, Ina S.
    Hilbrands, Luuk B.
    Figdor, Carl G.
    de Vries, I. Jolanda M.
    Adema, Gosse J.
    CLINICAL CANCER RESEARCH, 2010, 16 (20) : 5067 - 5078
  • [20] A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors.
    Calvo, Emiliano
    Moreno, Victor
    Perets, Ruth
    Yablonski-Peretz, Tamar
    Fourneau, Nele
    Girgis, Suzette
    Guo, Yue
    Hellemans, Peter
    Hokey, David
    Pendas Franco, Natalia
    Xia, Qi
    Geva, Ravit
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345